These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17409308)

  • 1. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.
    Schiffmann R; Askari H; Timmons M; Robinson C; Benko W; Brady RO; Ries M
    J Am Soc Nephrol; 2007 May; 18(5):1576-83. PubMed ID: 17409308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
    Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
    Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease.
    Schiffmann R; Swift C; Wang X; Blankenship D; Ries M
    J Inherit Metab Dis; 2015 Nov; 38(6):1129-36. PubMed ID: 25900714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
    Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
    Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
    Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
    J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
    Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment switch in Fabry disease- a matter of dose?
    Lenders M; Nordbeck P; Canaan-Kühl S; Kreul L; Duning T; Lorenz L; Pogoda C; Brand SM; Wanner C; Brand E
    J Med Genet; 2021 May; 58(5):342-350. PubMed ID: 32522756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
    Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
    Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agalsidase alfa and kidney dysfunction in Fabry disease.
    West M; Nicholls K; Mehta A; Clarke JT; Steiner R; Beck M; Barshop BA; Rhead W; Mensah R; Ries M; Schiffmann R
    J Am Soc Nephrol; 2009 May; 20(5):1132-9. PubMed ID: 19357250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).
    Suzuki K; Miura N; Kitagawa W; Suzuki S; Komatsuda A; Nishikawa K; Watanabe D; Imai H
    Clin Exp Nephrol; 2011 Dec; 15(6):916-20. PubMed ID: 21755431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.